Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome

Trial Profile

Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors G-treeBNT
  • Most Recent Events

    • 06 Aug 2015 Status changed from planning to not yet recruiting according to RegeneRx media release.
    • 17 Jul 2015 According to RegeneRx media release, company has recently received an IND for this trial.
    • 17 Feb 2015 According to a RegenRx media release, G-treeBNT filed an IND for this phase IIb/III trial in South Korea in Dec 2014, it is expected to be initiated in 2015, with results in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top